SCHEMBL3565153

SCHEMBL3565153

Cc1c(C(=O)Nc2ccc(Oc3ccc4nc(NC(=O)O)[nH]c4c3)cc2)c(=O)n(-c2ccccc2)n1CC(C)(C)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.53
MET P08581 8/20 0.53
IGF1R P08069 3/20 0.53
MST1R Q04912 2/20 0.53
TEK Q02763 8/20 0.49
AURKA O14965 1/20 0.49
JAK2 O60674 1/20 0.49
RPS6KA5 O75582 1/20 0.49
ABL1 P00519 1/20 0.49
INSR P06213 1/20 0.49
LCK P06239 1/20 0.49
FES P07332 1/20 0.49
CSF1R P07333 1/20 0.49
LYN P07948 1/20 0.49
RET P07949 1/20 0.49
FGR P09769 1/20 0.49
KIT P10721 1/20 0.49
PIM1 P11309 1/20 0.49
FGFR1 P11362 1/20 0.49
SRC P12931 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL783497 0.95 KDR (0.57) KDRMETIGF1RMST1RTEK
SCHEMBL199687 0.88 MET (0.51) KDRMETIGF1RMST1RTEK
SCHEMBL790668 0.78 MET (0.49) KDRMETIGF1RMST1RTEK
SCHEMBL12786992 0.77 MET (0.59) KDRMETIGF1RMST1RTEK
SCHEMBL723553 0.74 MET (0.61) KDRMETIGF1RMST1RTEK
SCHEMBL2950401 0.72 MET (0.53) KDRMETIGF1RMST1RTEK
SCHEMBL198269 0.72 MET (0.73) KDRMETIGF1RMST1RTEK
SCHEMBL2945807 0.72 MET (0.60) KDRMETIGF1RMST1RTEK
SCHEMBL15844536 0.71 MET (0.56) KDRMETIGF1RMST1RTEK
SCHEMBL198622 0.71 MET (0.70) KDRMETIGF1RMST1RTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET KDR 200/4885MET 3/4885IGF1R 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.